In addition, upregulation of EZH2 expression enhances SCLC progression and radioresistance (Zhai et al., 2020),Eric E Gardner et al. found that in patient-derived xenograft models of SCLC, adding EZH2 inhibitors to standard chemotherapy regimens can prevent the emergence of acquired drug resistance and enhance the chemotherapy sensitivity of SLCL (Gardner et al., 2017). Here, EZH2 is linked to small cell lung carcinoma.